Derivative exercise or conversion — not an open-market buy.
Traded Dec 4, 2025 · Filed Dec 5, 2025
Balchem's SVP and GM, Specialty Products sold $271K of Balchem shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$271,464
Shares × reported transaction price
44 days after results of Oct 21, 2025, 78 days before results of Feb 20, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.7% | −0.4% | +8.1% |
| 30 days | +5.0% | +0.9% | +4.1% |
| 90 days | +17.2% | −0.8% | +17.9% |
| 180 days | +7.7% | +8.1% | −0.4% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
A board member of Balchem sold $923K of Balchem shares. Nobody planned it ahead of time.